Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30576791 | 0.87 | ALDH1A1 (0.65) | KMT2AALDH1A1L3MBTL1GAATDP1 | |
| SCHEMBL2398664 | 0.87 | ALDH1A1 (0.65) | KMT2AALDH1A1L3MBTL1GAATDP1 | |
| SCHEMBL4559529 | 0.86 | KMT2A (0.78) | KMT2AALDH1A1L3MBTL1TDP1POLB | |
| SCHEMBL4558906 | 0.82 | CCNC (0.52) | KMT2AALDH1A1L3MBTL1POLBMEN1 | |
| SCHEMBL29832051 | 0.80 | TDP1 (0.76) | KMT2AALDH1A1GAATDP1KDM4E | |
| SCHEMBL8110954 | 0.79 | GAA (0.75) | KMT2AALDH1A1L3MBTL1GAAPOLB | |
| SCHEMBL4558440 | 0.79 | NPC1 (0.57) | KMT2AALDH1A1L3MBTL1POLBMEN1 | |
| SCHEMBL4559520 | 0.78 | L3MBTL1 (0.61) | KMT2AALDH1A1L3MBTL1TDP1KDM4E | |
| SCHEMBL4559727 | 0.77 | SMN1; SMN2 (0.52) | KMT2AALDH1A1L3MBTL1GAATDP1 | |
| SCHEMBL4559701 | 0.76 | ABCC1 (0.54) | KMT2AALDH1A1L3MBTL1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501407-B2 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| EP-1465631-A4 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1465631-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003053366-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | KMT2A 2079/4885ALDH1A1 2146/4885L3MBTL1 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.